These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

413 related items for PubMed ID: 16900013

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Blood pressure variability: clinical implications and effects of antihypertensive treatment.
    Parati G, Ravogli A, Frattola A, Groppelli A, Ulian L, Santucciu C, Mancia G.
    J Hypertens Suppl; 1994 Jul; 12(5):S35-40. PubMed ID: 7965285
    [Abstract] [Full Text] [Related]

  • 3. Blood pressure variability and organ damage.
    Mancia G, Frattola A, Parati G, Santucciu C, Ulian L.
    J Cardiovasc Pharmacol; 1994 Jul; 24 Suppl A():S6-11. PubMed ID: 7603077
    [Abstract] [Full Text] [Related]

  • 4. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 5. Reduction of blood pressure variability: a new strategy for the treatment of hypertension.
    Su DF, Miao CY.
    Trends Pharmacol Sci; 2005 Aug; 26(8):388-90. PubMed ID: 15990175
    [Abstract] [Full Text] [Related]

  • 6. Blood pressure variability is more important than blood pressure level in determination of end-organ damage in rats.
    Miao CY, Xie HH, Zhan LS, Su DF.
    J Hypertens; 2006 Jun; 24(6):1125-35. PubMed ID: 16685213
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Importance of blood pressure variability in organ protection in spontaneously hypertensive rats treated with combination of nitrendipine and atenolol.
    Xie HH, Miao CY, Liu JG, Su DF.
    Acta Pharmacol Sin; 2002 Dec; 23(12):1199-204. PubMed ID: 12466061
    [Abstract] [Full Text] [Related]

  • 9. Discordant effects of beta-blockade on central aortic systolic and brachial systolic blood pressure: considerations beyond the cuff.
    Epstein BJ, Anderson S.
    Pharmacotherapy; 2007 Sep; 27(9):1322-33. PubMed ID: 17723086
    [Abstract] [Full Text] [Related]

  • 10. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Devereux RB, Dahlöf B.
    Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
    [Abstract] [Full Text] [Related]

  • 11. Improvement of organ damage by a non-depressor dose of imidapril in diabetic spontaneously hypertensive rats.
    Tomita N, Yamasaki K, Izawa K, Kunugiza Y, Osako MK, Ogihara T, Morishita R.
    Int J Mol Med; 2007 Apr; 19(4):571-9. PubMed ID: 17334632
    [Abstract] [Full Text] [Related]

  • 12. Sympathetic activity, blood pressure variability and end organ damage in hypertension.
    Mancia G, Di Rienzo M, Parati G, Grassi G.
    J Hum Hypertens; 1997 Aug; 11 Suppl 1():S3-8. PubMed ID: 9321734
    [Abstract] [Full Text] [Related]

  • 13. Rat chromosome 19 transfer from SHR ameliorates hypertension, salt-sensitivity, cardiovascular and renal organ damage in salt-sensitive Dahl rats.
    Wendt N, Schulz A, Siegel AK, Weiss J, Wehland M, Sietmann A, Kossmehl P, Grimm D, Stoll M, Kreutz R.
    J Hypertens; 2007 Jan; 25(1):95-102. PubMed ID: 17143179
    [Abstract] [Full Text] [Related]

  • 14. Benazepril, an angiotensin-converting enzyme inhibitor, alleviates renal injury in spontaneously hypertensive rats by inhibiting advanced glycation end-product-mediated pathways.
    Liu XP, Pang YJ, Zhu WW, Zhao TT, Zheng M, Wang YB, Sun ZJ, Sun SJ.
    Clin Exp Pharmacol Physiol; 2009 Mar; 36(3):287-96. PubMed ID: 19018797
    [Abstract] [Full Text] [Related]

  • 15. Blood pressure variability, baroreflex sensitivity and organ damage in spontaneously hypertensive rats treated with various antihypertensive drugs.
    Xie HH, Shen FM, Zhang XF, Jiang YY, Su DF.
    Eur J Pharmacol; 2006 Aug 14; 543(1-3):77-82. PubMed ID: 16808912
    [Abstract] [Full Text] [Related]

  • 16. Mediators of target organ damage in hypertension: focus on obesity associated factors and inflammation.
    Dawood T, Schlaich MP.
    Minerva Cardioangiol; 2009 Dec 14; 57(6):687-704. PubMed ID: 19942842
    [Abstract] [Full Text] [Related]

  • 17. Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin.
    Lebel M, Rodrigue ME, Agharazii M, Larivière R.
    Am J Hypertens; 2006 Dec 14; 19(12):1286-92. PubMed ID: 17161776
    [Abstract] [Full Text] [Related]

  • 18. Antihypertensive pharmacological agents: beyond their lowering blood pressure effects.
    Miatello RM.
    Cell Mol Biol (Noisy-le-grand); 2005 Nov 08; 51(6):521-3. PubMed ID: 16309575
    [No Abstract] [Full Text] [Related]

  • 19. Left ventricular hypertrophy and clinical outcomes in hypertensive patients.
    Ruilope LM, Schmieder RE.
    Am J Hypertens; 2008 May 08; 21(5):500-8. PubMed ID: 18437140
    [Abstract] [Full Text] [Related]

  • 20. Transient prehypertensive treatment in spontaneously hypertensive rats: a comparison of spironolactone and losartan regarding long-term blood pressure and target organ damage.
    Baumann M, Hermans JJ, Janssen BJ, Peutz-Kootstra C, Witzke O, Heemann U, Smits JF, Boudier HA.
    J Hypertens; 2007 Dec 08; 25(12):2504-11. PubMed ID: 17984673
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.